Schwab US Dividend Equity ETF Experiences Big Inflow
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
SCHD Share Price Analysis: SCHD's current share price is $28.02, with a 52-week low of $25.16 and a high of $29.72, indicating its performance within the past year.
ETFs Trading Dynamics: Exchange traded funds (ETFs) function similarly to stocks, allowing for the buying and selling of units, which can be created or destroyed based on investor demand, impacting the underlying assets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 208.420
Low
223.00
Averages
252.00
High
289.00
Current: 208.420
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
Analysis of AbbVie's Shareholding Changes
- Number of Holding Funds: As of March 31, 2026, 34 hedge funds held AbbVie (Ticker: ABBV), indicating ongoing market interest despite mixed positions among these funds.
- Position Changes: In this latest batch of 13F filings, 14 funds increased their ABBV holdings while 15 decreased them, suggesting divergent market views that could impact stock price volatility.
- Aggregate Holding Increase: Hedge funds' total ABBV holdings reached 13,835,675 shares as of March 31, 2026, up from 13,068,029 shares on December 31, 2025, reflecting an increase of 767,646 shares or approximately 5.87%, indicating overall bullish sentiment towards ABBV.
- Key Fund Movements: Capital Advisory Group Advisory Services LLC and Bright Futures Wealth Management LLC exited their ABBV positions during this period, signaling a shift in perspective among some funds that may affect investor confidence.
See More
Three High-Yield Stocks for Investors
- AbbVie's Stability: AbbVie saw a revenue increase of about 9% last year, primarily driven by strong performance in its immunology and neuroscience segments, making it a reliable investment during economic fluctuations, with a current dividend yield of 3.3%, significantly above the S&P 500's 1.2%.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it offers a dividend yield of 3.8%, showcasing its strong profitability in a high oil price environment, with operating profits exceeding $16 billion annually over the past four years.
- Vici Properties' Diversification: Vici Properties boasts a high dividend yield of 6.3%, with last year's revenue rising by 4% to over $4 billion and net income climbing to $2.8 billion, demonstrating its ability to withstand economic downturns, as evidenced by an almost 8% stock price increase in 2022.
- Investment Value Emergence: These three stocks have shown exceptional performance during market turbulence, with AbbVie and Chevron providing stable income and Vici Properties offering high dividends, making them top choices for investors, especially amid increasing economic uncertainty.
See More
High Dividend Stock Investment Opportunities
- AbbVie's Stability: AbbVie saw a revenue increase of approximately 9% last year, driven by strong performance in its immunology and neuroscience segments, with a current dividend yield of 3.3%, nearly three times the S&P 500's 1.2%, highlighting its investment appeal during economic fluctuations.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it currently offers a dividend yield of 3.8%, with operating profits exceeding $16 billion annually over the past four years, demonstrating its strong financial performance in a high oil price environment.
- Vici Properties' High Yield: Vici Properties boasts a dividend yield of 6.3%, and its diversified real estate portfolio allows it to remain stable even in economic downturns, with a nearly 8% stock price increase in 2022, resulting in a total return of 13%, showcasing its potential as a safe investment.
- Market Performance and Investment Value: Although Vici Properties has slightly underperformed the S&P 500 this year with about a 1% increase, its strong dividend and solid financial foundation make it a noteworthy investment option to consider right now.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
Analysis of AbbVie's Shareholding Changes
- Number of Holding Funds: As of March 31, 2026, 34 hedge funds held AbbVie (Ticker: ABBV), indicating ongoing market interest despite mixed positions among these funds.
- Position Changes: In this latest batch of 13F filings, 14 funds increased their ABBV holdings while 15 decreased them, suggesting divergent market views that could impact stock price volatility.
- Aggregate Holding Increase: Hedge funds' total ABBV holdings reached 13,835,675 shares as of March 31, 2026, up from 13,068,029 shares on December 31, 2025, reflecting an increase of 767,646 shares or approximately 5.87%, indicating overall bullish sentiment towards ABBV.
- Key Fund Movements: Capital Advisory Group Advisory Services LLC and Bright Futures Wealth Management LLC exited their ABBV positions during this period, signaling a shift in perspective among some funds that may affect investor confidence.
See More
Three High-Yield Stocks for Investors
- AbbVie's Stability: AbbVie saw a revenue increase of about 9% last year, primarily driven by strong performance in its immunology and neuroscience segments, making it a reliable investment during economic fluctuations, with a current dividend yield of 3.3%, significantly above the S&P 500's 1.2%.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it offers a dividend yield of 3.8%, showcasing its strong profitability in a high oil price environment, with operating profits exceeding $16 billion annually over the past four years.
- Vici Properties' Diversification: Vici Properties boasts a high dividend yield of 6.3%, with last year's revenue rising by 4% to over $4 billion and net income climbing to $2.8 billion, demonstrating its ability to withstand economic downturns, as evidenced by an almost 8% stock price increase in 2022.
- Investment Value Emergence: These three stocks have shown exceptional performance during market turbulence, with AbbVie and Chevron providing stable income and Vici Properties offering high dividends, making them top choices for investors, especially amid increasing economic uncertainty.
See More
High Dividend Stock Investment Opportunities
- AbbVie's Stability: AbbVie saw a revenue increase of approximately 9% last year, driven by strong performance in its immunology and neuroscience segments, with a current dividend yield of 3.3%, nearly three times the S&P 500's 1.2%, highlighting its investment appeal during economic fluctuations.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it currently offers a dividend yield of 3.8%, with operating profits exceeding $16 billion annually over the past four years, demonstrating its strong financial performance in a high oil price environment.
- Vici Properties' High Yield: Vici Properties boasts a dividend yield of 6.3%, and its diversified real estate portfolio allows it to remain stable even in economic downturns, with a nearly 8% stock price increase in 2022, resulting in a total return of 13%, showcasing its potential as a safe investment.
- Market Performance and Investment Value: Although Vici Properties has slightly underperformed the S&P 500 this year with about a 1% increase, its strong dividend and solid financial foundation make it a noteworthy investment option to consider right now.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
